1 |
Kaminsky, L. S. and Fasco, M. J. (1991) Small intestinal cytochromes P450. Crit. Rev. Toxicol. 21, 407-422.
|
2 |
Kivisto, K. T. and Neuvonen, P. J. (1991) Enhancement of absortion and effect of glipizide by magnesium hydroxide. Clin. Pharmacol. Ther. 49, 39-43.
DOI
|
3 |
Kolars, J. C., Schmiedlin-Ren, P., Schuetz, J. D., Fang, C. and Watkins, P. B. (1992) Identifi cation of rifampin-inducible P450IIIA4 (CYP2C9) in human small bowel enterocytes. J. Clin. Invest. 90, 1871-1878.
DOI
|
4 |
Kradjan, W. A., Takeuchi, K. Y., Opheim, K. E. and Wood, F. C. Jr. (1995) Pharmacokinetics and pharmacodynamics of glipizide after once-daily and divided doses. Pharmacotherapy 15, 465-471.
|
5 |
Arauz-Pacheco, C., Ramirez, L. C., Rios, J. M. and Raskin, P. (1990) Hypoglycemia induced by angiotensin-converting enzyme inhibitors in patients with non-insulin dependent diabetes recieving sulfonylurea therapy. Am. J. Med. 89, 811-813.
DOI
|
6 |
Bart, J., Dijkers, E. C. Wegman, T. D., de Vries, E. G., van der Graaf, W. T., Groen, H. J., Vaalburg, W., Willemsen, A. T. and Hendrikse, N. H. (2005) New positron emission tomography tracer [(11)C] carvedilol reveals P-glycoprotein modulation kinetics. Br. J. Pharmacol. 145, 1045-1051
DOI
|
7 |
Bristow, M. R., Gilbert, E. M., Abraham, W. T., Adams, K. F., Fowler, M. B., Hershberger, R. E., Kubo, S. H., Narahara, K. A., Ingersoll, H., Krueger, S., Young, S. and Shusterman, N. (1996) Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 94, 2807-2816.
DOI
ScienceOn
|
8 |
Bristow, M. R., Larrabee, P., Minobe, W., Roden, R., Skerl, L., Klein, J., Handwerger, D., Port, J. D. and Müller-Beckmann, B. (1992) Receptor pharmacology of carvedilol in the human heart. J. Cardiovasc. Pharmacol. 19, S68-80.
DOI
|
9 |
Wahlin-Boll, E., Almer, L. O. and Melander, A. (1982) Bioavailability, pharmacokinetics and effects of glipizide in type 2 diabetics. Clin. Pharmacokinet. 7, 363-372.
DOI
|
10 |
Zarghi, A., Foroutan, S. M., Shafaati, A. and Khoddam, A. (2007) Quantifi cation of carvedilol in human plasma by liquid chromatography using fl uorescence detection: application in pharmacokinetic studies. J. Pharm. Biomed. Anal. 44, 250-253.
DOI
|
11 |
Connacher, A. A., el Debani, A. H., Isles, T. E. and Stevenson, I. H. (1987) Disposition and hypoglycaemic action of glipizide in diabetic patients given a single dose of nifedipine. Eur. J. Clin. Pharmacol. 33, 81-83.
DOI
|
12 |
Cao, X., Gibbs, S. T., Fang, L., Miller, H. A., Landowski, C. P., Shin, H. C., Lennernas, H., Zhong, Y., Amidon, G. L., Yu, L. X. and Sun, D. (2006) Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm. Res. 23, 1675-1686.
DOI
|
13 |
Choi, J. S. and Choi, D. H. (2010) Pharmacokinetic drug interaction between carvedilol and ticlopidine in rats. Bio. Ther. 18, 343-349.
과학기술학회마을
DOI
|
14 |
Cleland, J. G., Bristow, M. R., Erdmann, E., Remme, W. J., Swedberg, K. and Waagstein, F. (1996) Beta-blocking agents in heart failure. Should they be used and how? Eur. Heart J. 17, 1629-1639.
DOI
ScienceOn
|
15 |
McTavish, D., Campoli-Richards, D. and Sorkin, E. M. (1993) Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic effi cacy. Drugs 45, 232-258.
|
16 |
Kradjan, W. A., Witt, D. M., Opheim, K. E. and Wood, F. C. Jr. (1994) Lack of interaction between glipizide and co-trimoxazole. J. Clin. Pharmacol. 34, 997-1002.
DOI
ScienceOn
|
17 |
Lewis, D. F. V. (1996) Cytochrome P450. Substrate specifi city and metabolism. In Cytochromes P450. Structure, Function, and Mechanism. pp. 122-123. Taylor & Francis, Bristol.
|
18 |
Lund-Johansen, P., Omvik, P., Nordrehaug, J. E. and White, W. (1992) Carvedilol in hypertension: effects on hemodynamics and 24-hour blood pressure. J. Cardiovasc. Pharmacol. 19, S27-34.
DOI
|
19 |
Morgan, T. (1994) Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin. Pharmacokinet. 26, 335-346.
DOI
|
20 |
Neugebauer, G., Akpan, W., von Mollendorff, E., Neubert, P. and Reiff, K. (1987) Pharmacokinetics and disposition of carvedilol in humans. J. Cardiovasc. Pharmacol. 11, S85-88.
|
21 |
Neugebauer, G. and Neubert, P. (1991) Metabolism of carvedilol in man. Eur. J. Drug Metab. Pharmacokinet. 16, 257-260.
DOI
|
22 |
Cournot, A., Lim, C., Duchier, J. and Safar, M. (1992) Hemodynamic effects of carvedilol after acute oral administration in hypertensive and normal subjects. J. Cardiovasc. Pharmacol. 19, S35-39.
|
23 |
Niemi, M., Backman, J. T., Neuvonen, P. J. and Kivisro, K. T. (2001) Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin. Pharmacol. Ther. 69, 400-406.
DOI
|
24 |
Oldham, H. G. and Clarke, S. E. (1997) In vitro identifi cation of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab. Dispos. 25, 970-977.
|
25 |
Paice, B. J., Paterson, K. R., and Lawson, D. H. (1985) Undesired effects of the sulphonylurea drugs. Adverse Drug React Acute Poisoning Rev. 4, 23-36.
|
26 |
Crespi, C. L., Miller, V. P. and Penman, B. W. (1997) Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem. 248, 188-190.
DOI
|
27 |
DasGupta, P., Broadhurst, P. and Lahiri, A. (1991)The effects of intravenous carvedilol, a new multiple action vasodilatory beta-blocker, in congestive heart failure. J. Cardiovasc. Pharmacol. 18, S12-16.
DOI
|
28 |
Feuerstein, G. Z., Bril, A. and Ruffolo, R. R. Jr. (1997) Protective effects of carvedilol in the myocardium. Am. J. Cardiol. 80, 41L-45L.
DOI
|
29 |
Hagmeyer, K. O. and Stein, J. (2001) Hepatotoxicity associated with carvedilol. Ann. Pharmacother. 35, 1364-1366.
DOI
|
30 |
Hampton, J. R. (1996) Beta-blockers in heart failure--the evidence from clinical trials. Eur. Heart J. 17, 17-20.
DOI
ScienceOn
|
31 |
Han, C. Y., Cho, K.B., Choi, H. S., Han, H. K. and Kang, K. W. (2008) Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells. Carcinogenesis 29, 1837-1844.
DOI
|